Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTONEL WITH CALCIUM (COPACKAGED) vs BINOSTO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone matrix and inhibiting farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway.
Treatment and prevention of postmenopausal osteoporosis,Treatment of glucocorticoid-induced osteoporosis,Treatment of Paget's disease of bone
Treatment of osteoporosis in postmenopausal women,Treatment of osteoporosis in men,Treatment of glucocorticoid-induced osteoporosis,Prevention of osteoporosis in postmenopausal women
Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.
70 mg orally once weekly
Terminal elimination half-life of risedronate is approximately 20 hours for the 5 mg daily dose and 480 hours for the 35 mg weekly dose due to prolonged retention in bone; clinically, the drug accumulates in bone and is slowly released.
Terminal elimination half-life is approximately 10 hours; clinical context: supports once-weekly dosing for osteoporosis
Risedronate is not metabolized and is eliminated unchanged primarily via renal excretion.
Not metabolized; excreted unchanged primarily via renal clearance.
Risedronate is eliminated primarily via renal excretion, with approximately 50% of an absorbed dose excreted unchanged in urine. Unabsorbed drug is eliminated in feces. Total clearance is about 100 m L/min.
Renal: 50% excreted unchanged in urine; fecal: 20% as unabsorbed drug; biliary: negligible
Risedronate is approximately 24% bound to plasma proteins.
Approximately 24% bound to plasma proteins (primarily albumin)
Volume of distribution for risedronate is approximately 6.3 L/kg, indicating extensive distribution into bone and other tissues.
Vd: 0.2 L/kg; clinical meaning: low distribution, confined primarily to plasma and bone surface
Oral bioavailability of risedronate is low, averaging 0.63% for the 5 mg tablet when taken under fasting conditions; administration with food reduces bioavailability significantly (by up to 50%).
Oral: 0.7% (range 0.4–1.0%) when taken with plain water under fasting conditions
Contraindicated if Cr Cl <30 m L/min. For Cr Cl 30-49 m L/min: no dose adjustment needed. For Cr Cl ≥50 m L/min: no adjustment.
Cr Cl <35 m L/min: not recommended; Cr Cl 35-60 m L/min: no adjustment needed; Cr Cl >60 m L/min: no adjustment needed
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C).
No dose adjustment required for mild to moderate hepatic impairment; not studied in severe impairment
Not indicated for use in pediatric patients. Safety and efficacy not established.
Not approved for pediatric use (safety and efficacy not established)
No specific dose adjustment required. Caution in patients with decreased renal function; monitor renal status. Increased risk of hypocalcemia if calcium intake inadequate.
No specific dose adjustment; consider renal function and comorbidities
None
None.
Hypocalcemia must be corrected before therapy,Severe renal impairment (Cr Cl <30 m L/min) is not recommended,Esophageal irritation: instruct patients to swallow with full glass of water and not to lie down for 30 minutes,Osteonecrosis of the jaw (rare, mainly with cancer doses),Atypical femur fractures (rare, with long-term use),Avoid concomitant use with other bisphosphonates
Risk of atypical femur fractures,Osteonecrosis of the jaw,Severe musculoskeletal pain,Hypocalcemia,Renal impairment,Esophageal irritation or ulceration if not taken properly
Hypocalcemia,Severe renal impairment (Cr Cl <30 m L/min),Inability to sit or stand upright for at least 30 minutes,Hypersensitivity to risedronate or any component,Use in patients with esophageal abnormalities that delay emptying (e.g., stricture, achalasia)
Hypocalcemia,Inability to stand or sit upright for at least 30 minutes,Severe renal impairment (Cr Cl <30 m L/min),Esophageal abnormalities that delay esophageal emptying
Risedronate absorption is significantly reduced by food, especially dairy products, calcium-rich foods, and beverages other than plain water. Avoid all food, beverages (except plain water), and other medications for at least 30 minutes after the dose. Calcium supplement should be taken with a meal to enhance absorption.
Food, beverages (including mineral water, coffee, orange juice, and milk), and other oral medications significantly reduce absorption. Must be taken with plain water only on an empty stomach. Avoid high-calcium foods (e.g., dairy, fortified juices) within 30 minutes of dosing. Separate from calcium supplements, antacids, and iron supplements by at least 30 minutes.
Risedronate: Pregnancy Category C. Bisphosphonates accumulate in bone and are released slowly; theoretical risk of fetal skeletal abnormalities if exposure occurs before or during pregnancy. No adequate studies in pregnant women; use only if clearly needed. Calcium carbonate: Generally considered safe but excessive doses may cause hypercalcemia-related fetal risks. First trimester: Limited data, avoid if possible. Second/third trimester: Use only if maternal benefit outweighs fetal risk.
Bisphosphonates, including BINOSTO (alendronate), are not recommended during pregnancy. First trimester: Limited data suggest no significant increase in major malformations, but risk cannot be excluded due to small sample sizes. Second and third trimesters: Potential risk of fetal skeletal abnormalities due to calcium homeostasis disruption. Alendronate is classified as FDA Pregnancy Category C.
Risedronate: Unknown if excreted in human milk; not recommended due to potential for bone growth inhibition. Calcium: Excreted in breast milk at normal maternal intake levels; no adverse effects reported. M/P ratio: Unknown for risedronate; calcium M/P ratio approximately 1.1.
Alendronate is excreted into human breast milk in low amounts; M/P ratio unknown. Due to potential for bone growth suppression in the infant, breastfeeding is not recommended during therapy. Consider alternative treatments if breastfeeding is necessary.
Risedronate: No specific dose adjustments are recommended in pregnancy due to lack of data; generally avoided. Calcium: No dose adjustment needed; maintain recommended daily intake (1000-1300 mg/day). Pregnancy may increase calcium absorption but no dose change required for supplementation.
No dose adjustments are recommended during pregnancy as the drug is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased renal clearance) may alter alendronate exposure, but no studies have evaluated dose modifications. Therapy should be discontinued if pregnancy is planned or confirmed.
Actonel (risedronate) with calcium (copackaged) is used for osteoporosis. Administer risedronate on an empty stomach with plain water, at least 30 minutes before first food, drink, or other medications. Wait at least 30 minutes after risedronate before taking the calcium supplement. Calcium can interfere with risedronate absorption.
Binosto (alendronate sodium effervescent tablet) is a bisphosphonate for osteoporosis. Administer immediately after dissolving in at least 4 oz of room temperature water; do not chew or suck tablets. Give at least 30 minutes before first food, beverage, or other medication of the day to ensure absorption and reduce esophageal irritation. Monitor for hypocalcemia and renal function (Cr Cl <35 m L/min contraindicated). Discontinue if severe bone, joint, or muscle pain occurs. Consider drug holidays after 5 years for low-risk patients.
Take the risedronate tablet first thing in the morning, at least 30 minutes before eating or drinking anything except plain water.,Swallow the risedronate tablet whole with a full glass of plain water (6-8 oz). Do not crush, chew, or suck the tablet.,Do not lie down for at least 30 minutes after taking risedronate to reduce risk of esophageal irritation.,After taking risedronate, wait at least 30 minutes before taking the calcium supplement provided in the copack.,Take the calcium supplement with food or after a meal to improve absorption and reduce stomach upset.,Report any symptoms of esophageal problems (difficulty or pain on swallowing, heartburn, or retrosternal pain) or jaw pain (possible osteonecrosis of the jaw).
Take Binosto first thing in the morning on an empty stomach with a full glass of plain water (4-6 oz). Do not use mineral water or other beverages.,Wait at least 30 minutes after taking the tablet before eating, drinking, or taking any other medications.,Dissolve the tablet completely in water before drinking. Do not chew or swallow the tablet whole.,Stay upright (sitting or standing) for at least 30 minutes after taking to prevent esophageal irritation.,Swallow quickly after dissolution to avoid incomplete dosing.,Report any difficulty swallowing, pain when swallowing, retrosternal pain, or new/worsening heartburn.,Take calcium and vitamin D supplements as directed, but separate from Binosto by at least 30 minutes.,Rapid weight loss or prolonged immobility may increase risk of adverse effects.,Annual dental exams and good oral hygiene are recommended; report any jaw pain or delayed healing after dental procedures.,Do not double the dose if missed; skip it and take the next day's dose as usual.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTONEL WITH CALCIUM (COPACKAGED) vs BINOSTO, answered by our medical review team.
ACTONEL WITH CALCIUM (COPACKAGED) is a Bisphosphonate and Calcium Supplement that works by ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.. BINOSTO is a Bisphosphonate that works by Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone matrix and inhibiting farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTONEL WITH CALCIUM (COPACKAGED) and BINOSTO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTONEL WITH CALCIUM (COPACKAGED) is: Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.. The standard adult dose of BINOSTO is: 70 mg orally once weekly. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTONEL WITH CALCIUM (COPACKAGED) and BINOSTO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTONEL WITH CALCIUM (COPACKAGED) is classified as Category C. Risedronate: Pregnancy Category C. Bisphosphonates accumulate in bone and are released slowly; theoretical risk of fetal skeletal abnormalities if exposure occurs before or during . BINOSTO is classified as Category C. Bisphosphonates, including BINOSTO (alendronate), are not recommended during pregnancy. First trimester: Limited data suggest no significant increase in major malformations, but ri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.